← Back to Search

Other

AZD5055 for Healthy Volunteers

Phase 1
Waitlist Available
Research Sponsored by AstraZeneca
Eligibility Criteria Checklist
Specific guidelines that determine who can or cannot participate in a clinical trial
Must have
Be between 18 and 65 years old
Timeline
Screening 3 weeks
Treatment Varies
Follow Up until follow-up (day 7 ± 1 for part 1 and day 15 ± 1 for part 2).
Awards & highlights

Study Summary

This trial tests how a drug is absorbed, how it affects the body, and how safe and tolerable it is for healthy people in China and Japan.

Timeline

Screening ~ 3 weeks
Treatment ~ Varies
Follow Up ~until follow-up (day 7 ± 1 for part 1 and day 15 ± 1 for part 2).
This trial's timeline: 3 weeks for screening, Varies for treatment, and until follow-up (day 7 ± 1 for part 1 and day 15 ± 1 for part 2). for reporting.

Treatment Details

Study Objectives

Outcome measures can provide a clearer picture of what you can expect from a treatment.
Primary outcome measures
Number of participants with adverse events
Secondary outcome measures
Area under plasma concentration-curve from time 0 to the last quantifiable concentration (AUClast)
Area under plasma concentration-time curve from time 0 to infinity (AUCinf)
Maximum serum concentration (Cmax)

Trial Design

2Treatment groups
Active Control
Placebo Group
Group I: AZD5055Active Control2 Interventions
Participants will orally receive AZD5055.
Group II: PlaceboPlacebo Group2 Interventions
Participants will orally receive placebo.

Find a Location

Logistics

Participation is compensated

You will be compensated for participating in this trial.

Who is running the clinical trial?

AstraZenecaLead Sponsor
4,259 Previous Clinical Trials
288,593,864 Total Patients Enrolled

Media Library

AZD5055 (Other) Clinical Trial Eligibility Overview. Trial Name: NCT05955183 — Phase 1
Healthy Subjects Research Study Groups: AZD5055, Placebo
Healthy Subjects Clinical Trial 2023: AZD5055 Highlights & Side Effects. Trial Name: NCT05955183 — Phase 1
AZD5055 (Other) 2023 Treatment Timeline for Medical Study. Trial Name: NCT05955183 — Phase 1

Frequently Asked Questions

These questions and answers are submitted by anonymous patients, and have not been verified by our internal team.

Is AZD5055 a risk-free option for individuals?

"AZD5055 is a relatively novel medication, so the safety score was estimated at 1. This reflects that it's in its early clinical trial phase with only limited outcome data available."

Answered by AI

Are there still vacancies available to participate in this trial?

"According to the info available on clinicaltrials.gov, this research initiative is no longer open for recruitment as of July 13th 2023. Nevertheless, there are still 798 other medical trials that currently require participants."

Answered by AI

Is this research accommodating elderly participants over 85 years of age?

"This trial has a specified age range of 18 - 55, with 56 trials for minors and 372 specifically designed to meet the needs of elderly patients."

Answered by AI

Am I eligible to enroll in this research trial?

"To be eligible to join this trial, potential participants should meet the criteria of being between 18-55 years and have healthy bodies. The total number of patients in the study is 40."

Answered by AI
~22 spots leftby Apr 2025